United States Patent 8,410,086: Claim Scope, Vascepa Exclusivity, and Patent Landscape

US Patent No. 8,410,086 protects a clinical-use method for administering highly purified ethyl eicosapentaenoate, or icosapent ethyl, at approximately 4 g/day to statin-treated patients with fasting triglycerides of 200 mg/dL to less than 500 mg/dL. The patent focuses on reductions in triglycerides and LDL-C after at least 12 weeks of treatment.

The patent is associated with Amarin’s Vascepa, whose active ingredient is icosapent ethyl. Its core protection is narrower than a composition patent because infringement depends on the patient population, background statin therapy, dose, EPA purity, treatment duration and lipid-lowering outcome.

What patent is US 8,410,086?

US 8,410,086 is titled “Methods of lowering triglycerides and LDL-C in a subject.” It was assigned to Amarin Pharmaceuticals Ireland Limited and issued on April 2, 2013. The patent claims methods of treating hypertriglyceridemic patients using a pharmaceutical composition containing at least approximately 96% ethyl eicosapentaenoate by weight of total fatty acids.

Item	Details
Patent number	US 8,410,086 B2
Title	Methods of lowering triglycerides and LDL-C in a subject
Applicant/assignee	Amarin Pharmaceuticals Ireland Limited
Filing date	December 14, 2010
Earliest priority date	December 14, 2009
Issue date	April 2, 2013
Active ingredient	Ethyl eicosapentaenoate, also called icosapent ethyl
Commercial product	Vascepa
Primary dosage	Approximately 4 g/day
Patient population	Fasting triglycerides of about 200 mg/dL to less than 500 mg/dL
Background therapy	Stable statin therapy
Minimum treatment duration	12 weeks for the principal claim set
Nominal patent expiration	December 14, 2030, before any applicable adjustment

The patent does not broadly claim all uses of fish oil, omega-3 fatty acids or icosapent ethyl. It claims a defined treatment protocol using a high-purity EPA ethyl ester product in a specified statin-treated population.

What do the independent claims of US 8,410,086 cover?

Claims 1, 6 and 10 are the principal independent claims.

Claim 1: clinical method with lipid endpoints

Claim 1 requires all of the following:

A subject with fasting triglycerides of about 200 mg/dL to less than 500 mg/dL.
Stable statin therapy.
Oral administration.
Approximately 4 g/day of the pharmaceutical composition.
A composition containing at least approximately 96% ethyl eicosapentaenoate by weight of all fatty acids.
Treatment for at least approximately 12 weeks.
A reduction in fasting triglycerides and fasting LDL-C compared with a statin-treated comparator who did not receive the composition.

This is a combination claim. Omitting any required element can create a non-infringement position, although the practical result depends on prescribing information, clinical data, product composition and how the claim is interpreted.

Claim 6: adds a five-percent reduction threshold

Claim 6 repeats the basic treatment framework but requires at least a 5% reduction in both fasting triglycerides and fasting LDL-C compared with the untreated statin comparator.

The 5% limitation narrows the claim relative to claim 1. It also creates a potential factual dispute over baseline values, statistical analysis, comparator selection and whether the claimed reduction is assessed at the patient level or population level.

Claim 10: population-based treatment method

Claim 10 is drafted differently. It covers administering the composition to a patient population that meets the triglyceride and statin-therapy criteria, where administration to a first patient population at 4 g/day for 12 weeks reduces fasting triglycerides and LDL-C compared with a second untreated statin-treated population.

Claim 10 is important because it refers to treatment effectiveness in patient populations rather than requiring a particular reduction in every treated individual. The claim is closely tied to clinical-trial evidence and statistical interpretation.

What do dependent claims 2 through 5 and 7 through 9 protect?

The dependent claims extend the lipid endpoints and patient profile.

Claim	Added limitation
2	Reduction in fasting non-HDL-C
3	Reduction in fasting VLDL-C
4	Reduction in fasting apolipoprotein B
5	Reduction in fasting total cholesterol
7	Reduction in fasting non-HDL-C under claim 6
8	At least 5% reduction in fasting LDL-C
9	Baseline LDL-C of approximately 40 mg/dL to 115 mg/dL
11	Statin is atorvastatin, rosuvastatin or simvastatin at about 10 mg to 100 mg/day
12	Same statin limitation under claim 6
13	Same statin limitation under claim 10

Claims 11 through 13 materially narrow the patent to three named statins. They are commercially relevant because Vascepa’s pivotal studies included patients receiving statin therapy, and generic labeling may instruct use in a population overlapping these limitations.

How strong is the patent estate for icosapent ethyl?

The ’086 patent is a method-of-use patent, not the principal composition patent for icosapent ethyl. Its strength depends on whether a competing product or label directs treatment into the claimed population.

Strengths

The patent has several technically specific limitations:

A narrow triglyceride range.
Stable statin therapy.
Approximately 4 g/day.
At least 96% EPA ethyl ester.
A minimum treatment duration.
Defined lipid reductions.
Named statins in dependent claims.

These limitations can make a direct invalidity challenge more difficult if the claims are supported by clinical data and the prior art does not disclose the full combination.

Weaknesses

The same limitations create enforcement risks:

A generic label may omit or alter the claimed LDL-C reduction language.
Doctors may prescribe outside the 200 mg/dL to less than 500 mg/dL range.
The product may be dispensed for cardiovascular-risk reduction rather than triglyceride lowering.
Direct infringement may depend on induced-infringement evidence.
“Stable statin therapy” can raise interpretation and proof issues.
The comparator language may complicate application to individual patients.
A 4 g/day regimen may be administered as two 2 g doses or four 1 g capsules, requiring product-label analysis rather than capsule-count analysis.

The patent is therefore stronger as a targeted Orange Book method patent than as a general barrier to all icosapent ethyl sales.

What is the FDA and Orange Book status of US 8,410,086?

Vascepa was approved by the FDA in July 2012 under NDA 202057 for severe hypertriglyceridemia. The FDA later expanded the indication to reduce cardiovascular risk in adults with elevated triglycerides and established cardiovascular disease or diabetes plus additional risk factors while taking maximally tolerated statin therapy.[1]

US 8,410,086 has been associated with the Vascepa patent estate and has been relevant to the product’s listed intellectual-property position. The Orange Book status of an individual patent can change through delisting, expiration, corrections or FDA publication updates. Patent listing does not itself establish validity or infringement.

FDA milestones

Date	Event
July 26, 2012	FDA approval of Vascepa for severe hypertriglyceridemia
December 2019	FDA approval of cardiovascular-risk-reduction indication based on REDUCE-IT
2020 onward	ANDA litigation and generic-entry disputes involving icosapent ethyl
December 14, 2030	Nominal expiration date for the ’086 patent based on the stated priority date

The product’s FDA-approved uses are broader than the claim scope of the ’086 patent in some respects. The cardiovascular-risk indication focuses on cardiovascular-event reduction, while the ’086 claims focus on triglyceride and LDL-C lowering in a defined population.

When does Vascepa lose exclusivity?

Vascepa’s exclusivity is controlled by several overlapping protections rather than one patent.

Protection type	Relevance
FDA orphan-drug exclusivity	Not the principal basis for Vascepa’s current market protection
New chemical entity exclusivity	Expired before the current patent disputes
Clinical-investigation exclusivity	Relevant to FDA approval timing but not a substitute for patent protection
Composition patents	Protect the icosapent ethyl product or pharmaceutical composition
Method-of-use patents	Protect selected patient populations and outcomes
Formulation patents	May protect capsule composition, dosage forms or manufacturing features
Regulatory listing	Allows patent-based Paragraph IV litigation under the Hatch-Waxman Act

The ’086 patent’s nominal expiration is December 14, 2030. That date should not be treated as the expiration date for the entire Vascepa estate. Other patents may expire earlier or later, and patent-term adjustment can alter the statutory term.

Which companies challenged Vascepa patents?

Generic icosapent ethyl litigation has involved major ANDA applicants, including Hikma Pharmaceuticals and Dr. Reddy’s Laboratories. The principal disputes centered on whether the asserted method patents were valid and whether generic labeling induced infringement.

The best-known proceeding was Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc. in the U.S. District Court for the District of Delaware. The dispute involved patents covering Vascepa methods of use and the treatment of patients with elevated triglycerides.[2]

The Federal Circuit affirmed a decision invalidating certain Amarin method claims for obviousness. The ruling materially weakened portions of Amarin’s method-of-use patent estate and enabled generic competition for approved uses not adequately protected by surviving claims.[3]

The litigation does not mean that every Vascepa patent, including every claim of the ’086 patent, was invalidated. Patent-by-patent and claim-by-claim analysis remains necessary.

What Paragraph IV risks exist for US 8,410,086?

An ANDA applicant can submit a Paragraph IV certification asserting that a listed patent is invalid, unenforceable or not infringed. A Paragraph IV filing can trigger a 45-day patent-infringement action and a potential 30-month stay of FDA approval under the Hatch-Waxman framework.[4]

For the ’086 patent, the main generic arguments would likely focus on:

Non-infringement

A generic applicant could attempt to avoid infringement by:

Omitting a claimed method-of-use indication from its label.
Avoiding express directions for treatment of LDL-C and triglycerides together.
Using labeling that does not identify the claimed patient range.
Challenging whether the label requires stable statin therapy.
Arguing that the label does not require treatment for at least 12 weeks.
Disputing whether the product contains at least 96% EPA by weight of all fatty acids.

Invalidity

Potential invalidity theories include:

Obviousness based on prior omega-3 treatment studies.
Anticipation by earlier icosapent ethyl or EPA disclosures.
Lack of written description for the precise clinical population or endpoint.
Lack of enablement for the full scope of the claimed treatment method.
Indefiniteness involving terms such as “stable statin therapy,” “about 4 g,” or population-level reductions.

The prior-art record is especially important because the claims combine a known active ingredient, a known dose and a specified patient population with clinical lipid outcomes. The patentability question turns on whether the claimed combination and results were predictable from the cited literature at the priority date.

Are biosimilar risks relevant to Vascepa?

No. Vascepa is a small-molecule drug, not a biologic. Biosimilar approval under the Public Health Service Act is not the relevant pathway.

Generic competition proceeds through ANDAs under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The relevant risks are Paragraph III and Paragraph IV certifications, label carve-outs, patent litigation, formulation equivalence and induced-infringement theories.[4]

What formulation patents protect icosapent ethyl?

The ’086 patent is primarily a therapeutic-use patent. It does not claim every physical formulation of icosapent ethyl.

The broader Vascepa estate has included patents directed to:

Highly purified EPA ethyl ester compositions.
Soft-gelatin capsule formulations.
Capsule dosage strengths.
Oxidative stability.
Manufacturing and purification methods.
Treatment of hypertriglyceridemia.
Cardiovascular-risk reduction.
Use with statins.

Composition and formulation patents generally create a different infringement profile from the ’086 patent. A generic may avoid a formulation claim through a different excipient system while still facing method-of-use claims. Conversely, a generic may omit a patented indication but still need to address composition or manufacturing patents.

How does the ’086 patent compare with competing omega-3 products?

Product	Principal active ingredient	EPA/DHA profile	Typical regulatory positioning	Relationship to ’086
Vascepa	Icosapent ethyl	Predominantly EPA ethyl ester	Hypertriglyceridemia and cardiovascular-risk reduction	Directly relevant
Lovaza	Omega-3-acid ethyl esters	EPA and DHA	Severe hypertriglyceridemia	Generally outside the 96% EPA limitation
Epanova	Omega-3 carboxylic acids	EPA and DHA	Development and regulatory history distinct from Vascepa	Different chemical form and composition
Generic icosapent ethyl	Icosapent ethyl	EPA-dominant	ANDA-based generic competition	Potentially within method claims

The 96% purity limitation distinguishes the claimed composition from mixed EPA/DHA products. A product containing substantial DHA or using a different chemical form may not satisfy the composition limitation, although it could implicate other patents.

What generic launch scenarios exist?

Three launch scenarios are commercially relevant.

Early launch after patent settlement

A generic company may settle litigation for a licensed launch date before patent expiration. Settlement terms may include entry timing, permitted indications and restrictions on promotion. Publicly available information does not establish that the ’086 patent alone determines the launch date.

Launch after successful Paragraph IV litigation

A generic may launch if the asserted patents are invalidated, found not infringed or removed as barriers to approval. The Federal Circuit’s Vascepa decisions reduced protection for certain method claims and increased this pathway’s commercial importance.[3]

Launch with a skinny label

A generic may carve out a patented indication or use under FDA rules. The commercial effect depends on whether the remaining label still encourages use that falls within a surviving method claim. A nominal carve-out does not eliminate induced-infringement risk if the label, marketing or prescribing information encourages the patented use.

What is the commercial exposure from loss of exclusivity?

Vascepa historically generated substantial revenue for Amarin, with U.S. sales concentrated in the statin-treated hypertriglyceridemia and cardiovascular-risk-reduction markets. Revenue exposure depends on:

The number of approved generic suppliers.
Generic launch timing.
Whether cardiovascular-risk reduction remains on generic labels.
Payer substitution policies.
Prescriber adherence to the branded label.
The surviving formulation and composition patents.
Settlement restrictions.
The extent of off-label prescribing.

Because the product is an oral small molecule with a conventional capsule presentation, manufacturing barriers are lower than for a biologic. The principal barriers are regulatory equivalence, intellectual-property litigation and commercial scale.

What geographic coverage does US 8,410,086 provide?

The ’086 patent is a U.S. patent. It provides no direct exclusionary rights in Canada, Europe, Japan or other jurisdictions.

Amarin’s international protection depends on corresponding national patents and local prosecution outcomes. Patent term, claim scope, listing systems and generic litigation procedures vary by country. U.S. Orange Book listing has no automatic legal effect outside the United States.

Key Takeaways

US 8,410,086 is a narrow method-of-use patent for 4 g/day of highly purified ethyl eicosapentaenoate.
The claimed population has fasting triglycerides of about 200 mg/dL to less than 500 mg/dL and stable statin therapy.
The composition must contain at least approximately 96% EPA ethyl ester by weight of all fatty acids.
Claims 1, 6 and 10 are the core independent claims.
Claims 6 and 8 add a 5% lipid-reduction threshold.
Claims 11 through 13 narrow the statin therapy to atorvastatin, rosuvastatin or simvastatin.
The nominal expiration date is December 14, 2030, subject to patent-term adjustment.
Vascepa is a small molecule, so generic ANDA litigation, not biosimilar litigation, is the relevant pathway.
Amarin’s broader method-of-use estate suffered important Federal Circuit losses, weakening the overall barrier to generic entry.
The ’086 patent should be analyzed separately from composition, formulation, manufacturing and cardiovascular-risk-reduction patents.
Generic launch risk depends on label design, Paragraph IV litigation, surviving patents and settlement terms.

Frequently Asked Questions

Does US 8,410,086 cover all icosapent ethyl products?

No. It covers specified treatment methods using a composition with at least approximately 96% ethyl eicosapentaenoate, administered at approximately 4 g/day to a defined statin-treated population.

Does the patent require Vascepa to be taken with a statin?

The independent claims require the treated subject to be on stable statin therapy. The dependent claims identify atorvastatin, rosuvastatin and simvastatin as specific statins.

Can a generic icosapent ethyl product avoid the patent through a label carve-out?

Potentially, but the result depends on the final label and commercial conduct. A carve-out may reduce infringement exposure but does not automatically eliminate induced-infringement risk.

Is the ’086 patent a formulation patent?

No. Its principal claims are clinical method claims. Other Vascepa patents address composition, formulation, manufacturing or additional therapeutic uses.

Does the patent protect cardiovascular-event reduction?

Not directly in the claims provided. The claims focus on reductions in triglycerides, LDL-C and related lipid parameters. Cardiovascular-event reduction is covered by separate regulatory and patent considerations.

References

U.S. Food and Drug Administration. (2012). Vascepa (icosapent ethyl) prescribing information. https://www.accessdata.fda.gov
Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., No. 20-cv-1630, U.S. District Court for the District of Delaware.
Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., 819 F. App’x 932 (Fed. Cir. 2020).
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,410,086: Methods of lowering triglycerides and LDL-C in a subject. https://patents.google.com/patent/US8410086B2/en

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Amarin Pharms	VASCEPA	icosapent ethyl	CAPSULE;ORAL	202057-001	Jul 26, 2012	AB	RX	Yes	Yes	8,410,086	⤷ Start Trial				USE OF VASCEPA TO LOWER TRIGLYCERIDES AND LDL-C IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON STATIN THERAPY	⤷ Start Trial
Amarin Pharms	VASCEPA	icosapent ethyl	CAPSULE;ORAL	202057-002	Feb 16, 2017	AB	RX	Yes	No	8,410,086	⤷ Start Trial				USE OF VASCEPA TO LOWER TRIGLYCERIDES AND LDL-C IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON STATIN THERAPY	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2443246	⤷ Start Trial	301137	Netherlands	⤷ Start Trial
European Patent Office	2443246	⤷ Start Trial	LUC00226	Luxembourg	⤷ Start Trial
European Patent Office	2443246	⤷ Start Trial	PA2021522	Lithuania	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,410,086

Which drugs does patent 8,410,086 protect, and when does it expire?

Summary for Patent: 8,410,086